NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 134774-45-1
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of rasbicurase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Rasburicase
CAS Registry Number
134774-45-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Pertuzumab[Drugs and Lactation Database (...]Review Pertuzumab. Drugs and Lactation Database (LactMed). 2006
- Review Obinutuzumab[Drugs and Lactation Database (...]Review Obinutuzumab. Drugs and Lactation Database (LactMed). 2006
- Review Dinutuximab[Drugs and Lactation Database (...]Review Dinutuximab. Drugs and Lactation Database (LactMed). 2006
- Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase.[Biotechnol Appl Biochem. 2002]Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase.Bayol A, Capdevielle J, Malazzi P, Buzy A, Claude Bonnet M, Colloc'h N, Mornon JP, Loyaux D, Ferrara P. Biotechnol Appl Biochem. 2002 Aug; 36(1):21-31.
- Review Nivolumab[Drugs and Lactation Database (...]Review Nivolumab. Drugs and Lactation Database (LactMed). 2006
- Rasburicase - Drugs and Lactation Database (LactMed)Rasburicase - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...